Central banks buying gold at the fastest monthly pace in nearly two years tells you one thing: big money is hunting for perceived resilience as worries over government finances and currencies build. That mindset can spill over into carefully selected low priced shares backed by solid balance sheets and limited dilution. This article walks through three such under the radar stocks and why they may deserve a place on your watchlist.
The three elite penny stocks profiled below are only a small sample. The wider screen surfaced 116 more companies that share similar balance sheet strength, low dilution and aligned insiders that are not covered here. If you want to identify and analyze the full set of high conviction setups instead of stopping at a handful of examples, head straight into the Elite Penny Stocks screener.
Nuvation Bio is a clinical-stage oncology specialist in the Elite Penny Stocks theme, with its story anchored to late-stage targeted cancer therapies that tie growth potential directly to concrete drug programs rather than a broad basket of experimental projects.
Nuvation Bio focuses on targeted cancer therapies, led by IBTROZI for ROS1+ non small cell lung cancer and safusidenib for high risk IDH1 mutant astrocytoma. The company reports about $169.9 million from oncology development activities and carries a market value of roughly $1.66b.
"IBTROZI is rapidly emerging as the preferred therapy in ROS1 positive non small cell lung cancer, with best in class durability, strong brain penetration and growing first line use."
For investors watching Nuvation Bio, the key issue is how one evolving pressure may influence the company’s future pricing power and margins.
Pricing power is only part of the picture, and the full narrative for Nuvation Bio maps how trial progress, capital allocation and dilution risks could be quietly reshaping Nuvation Bio’s trajectory.
PagSeguro Digital is a Brazilian fintech that uses its PagBank digital banking and card platform to deliver payments, deposits and credit services, generating about R$19.8b from financial service agents and carrying a market value near US$3b.
PagSeguro earns a place in the Elite Penny Stocks screen because PagBank connects low cost digital accounts, cards and credit into one ecosystem that can turn small merchants into steady fee and interest revenue, in a sector where balance sheet strength and dilution discipline really matter.
"The single biggest lever is the credit portfolio. If that portfolio seasons badly in a Brazilian downturn, the credit engine that drives my earnings growth becomes a source of losses instead."
What matters most from here is how one still developing shift in the business mix filters through to profitability and capital returns.
That hinges on where risk really sits in PagBank’s engine, and the full narrative for PagSeguro Digital shows how credit quality, funding costs and fee income could be quietly decoupling.
Hour Glass runs a luxury watch and jewellery retail network tied directly to the Elite Penny Stocks luxury theme, generating about S$1.34b from selling high end products through boutiques and distributors, and carries a market value near S$1.6b.
Hour Glass combines a premium watch retail focus with fundamentals that fit the Elite Penny Stocks idea, trading on a P/E of about 9x while earning 16.6% ROE and 13.4% net margins. That mix of value and profitability only holds depending on how one unresolved shift in luxury demand plays out.
That unresolved demand shift is exactly why the analysis report for Hour Glass could help you see whether Hour Glass’s current profitability is masking a bigger inflection point ahead
Fresh ideas move first. The most interesting shares often gain momentum quietly, then start breaking out while many investors are caught watching old stories. Scan these under the radar lists while it matters and get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com